Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- Japan PBSS Launches to Buttress Drug Discovery via Grassroots Networks
November 26, 2025
- Labor Group Presses Lawmakers to Reflect Rising Costs in Drug Prices
November 26, 2025
- Industry Groups Call for More Efficient Clinical Trials in Japan: Joint Statement
November 21, 2025
- PhRMA Chief Warns Japan Is Losing Its Appeal, Urges End to On-Patent Price Cuts
November 19, 2025
- Policy Veterans’ Group Calls for Value-Based Pricing for Regenerative Medicine
November 14, 2025
- JPMA Exec Urges Immediate Action on Inflation Pressures as Budget Talks Loom
November 14, 2025
- JPMA’s Yoshida Urges Pro-Innovation Rules to Boost Japan’s Appeal amid MFN Fears
November 11, 2025
- Labor Union Calls for Uniform Hike in Drug Prices, Lawmakers Urge Overhaul
October 29, 2025
- JMA Renews Opposition to Insurance Review for OTC-Like Drugs
October 24, 2025
- MFN Drug Pricing Already Affecting 4 Firms’ R&D Plans in Japan, EFPIA Chief Flags Fallout
October 22, 2025
- JPMA Chief Hails Takaichi’s Election as PM, Calls for Stronger Innovation Ecosystem
October 22, 2025
- Wholesalers to Broaden Lobbying Push to Include Ishin amid Political Shift: Leader
October 17, 2025
- JPMA Chief Renews Call for Reflecting Inflation and Wage Hikes in Drug Pricing
October 17, 2025
- Pharma-Cosmetic Union Officially Joins Rengo as Associate Organization
October 9, 2025
- NPhA Urges Pharmacies to Provide Accurate Info on Acetaminophen Use during Pregnancy
October 6, 2025
- Japan Patient Group Calls for Dupixent Approval in Ichthyosis
October 6, 2025
- Think Tanks Urge Unique Value Framework for Regenerative Medicine in 2026 Reform
October 2, 2025
- JETRO Launches Japan Entry Program for Regenerative Medicine Startups
October 2, 2025
- Policy Veterans’ Group Calls for Inflation-Linked Drug Pricing in FY2026 Reform
October 1, 2025
- Generic Use Rate Hits Record 89.2% in April-June: JGA
September 29, 2025
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…